Key facts about lobular carcinoma in situ (LCIS) and atypical ductal or lobular hyperplasia: ⭐️ What they are and how they increase breast cancer risk ⭐️ Do they need surgery? ⭐️ When do we think about endocrine therapy (tamoxifen or aromatase inhibitors) Bottom line: these are conditions that can increase your breast cancer  risk in the future and we think about using endocrine therapy to lower that risk. Endocrine therapy can reduce risk of future breast cancer by 50% when given for LCIS or a

“Do I really need to do this to myself?” That’s a question many women wonder when diagnosed with ductal carcinoma in situ (DCIS) and faced with surgery and radiation as the current standard treatment. Now, early results of a study led by Duke Cancer Institute surgeon Dr. E. Shelley Hwang reveal DCIS patients who practice “watchful waiting” are no more at risk of developing invasive breast cancer than women who undergo surgery to remove the precancerous cells. The COMET Study was presented at the